Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alison Turner

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian CancerSusana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.
Clinical and Vaccine Immunology : CVI|January 18, 2013
A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection modelNicola L Davies, Joanne E Compson, Brendon Mackenzie, et al.
Journal for Immunotherapy of Cancer|June 18, 2022
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumorsDionysis Papadatos-Pastos, Wei Yuan, Abhijit Pal, et al.
Cancer Discovery|September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Joline S J Lim, Iain R Macpherson, et al.
Cancer Discovery|June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant CancersTimothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Nature|October 16, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Adam Sharp, Bora Gurel, et al.
Science Translational Medicine|October 5, 2021
An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal modelsBert Schepens, Loes van Schie, Wim Nerinckx, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian CancerSusana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.
Clinical and Vaccine Immunology : CVI|January 18, 2013
A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection modelNicola L Davies, Joanne E Compson, Brendon Mackenzie, et al.
Journal for Immunotherapy of Cancer|June 18, 2022
Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumorsDionysis Papadatos-Pastos, Wei Yuan, Abhijit Pal, et al.
Cancer Discovery|September 22, 2020
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i>-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid CancersJavier Pascual, Joline S J Lim, Iain R Macpherson, et al.
Cancer Discovery|June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant CancersTimothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.
Nature|October 16, 2023
Targeting myeloid chemotaxis to reverse prostate cancer therapy resistanceChristina Guo, Adam Sharp, Bora Gurel, et al.
Science Translational Medicine|October 5, 2021
An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal modelsBert Schepens, Loes van Schie, Wim Nerinckx, et al.
Pageof 5